SkimSkim home
In deliveryUnited KingdomGoodsFramework agreement£1,520,432,295

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Awarded to ABBVIE LTD, ALIMERA SCIENCES LIMITED, Abbvie Ltd +22 more

NHS ENGLAND(buyer)

Published
Published 19 June 2025
Deadline
Closed 14 July 2025
See 13 live opportunitiesHow Skim finds tendersView original notice ↗

Tender documents

Skim pulls every file the buyer attaches to this process and extracts the requirements from it.

Documents as they publish

Specification, evaluation criteria, pricing schedules and every requirement — extracted, searchable and mapped to your response.

View tender files

Overview

NHS England has awarded a national framework for medical retinal vascular treatments with call-offs running from 1 December 2025 to 31 May 2027, with options to extend up to 24 months. The framework covers the supply of licensed anti-VEGF and intravitreal corticosteroid medicines including aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab for treating conditions such as wet age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, myopic choroidal neovascularisation, retinopathy of prematurity and non-infectious uveitis. The award, valued at £2,254,670,118, was made to 21 suppliers including AbbVie, Alimera Sciences, Bayer, Biogen, Celltrion, Novartis, Orion Pharma, Outlook Therapeutics, Roche, Sandoz, Teva and others.

Contracting authority

  • NHS ENGLANDBuyer

    13 live opportunities · 817 awarded contracts

    Leeds, United Kingdom

    GB-NHS: X24

  • NHS England

    Buyer

    London, United Kingdom

    GB-PPON: PDPT-3135-BWWY

    Authority website ↗

Find the key decision makers

The people who scope, score and sign this contract — names, roles and how to reach them.

Reveal decision makers

Lots (2)

  • CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

    CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National)

    £1,471,752,146Won by Bayer PlcWon by BIOSIMILAR COLLABORATIONS IRELAND LIMITEDWon by Celltrion Healthcare United Kingdom LimitedWon by MDBIOLOGICS LTDWon by SANDOZ LIMITEDWon by ABBVIE LTDWon by ALIMERA SCIENCES LIMITEDWon by BIOGEN IDEC LIMITEDWon by ROCHE PRODUCTS LIMITEDWon by NOVARTIS PHARMACEUTICALS UK LIMITEDWon by ORION PHARMA (UK) LIMITEDWon by Outlook Therapeutics, Inc.Won by TEVA UK LIMITEDWon by THORNTON & ROSS LIMITEDWon by BAYER PUBLIC LIMITED COMPANYWon by CELLTRION HEALTHCARE UNITED KINGDOM LIMITEDWon by MDBIOLOGICS LTDWon by SANDOZ LIMITEDWon by Abbvie LtdWon by Alimera SciencesWon by BiogenWon by Novartis Pharmaceuticals UK LtdWon by Orion Pharma (UK) LtdWon by Outlook Therapeutics, Inc.Won by Roche Products LtdWon by Teva UK LimitedWon by Thornton and Ross Ltd

  • CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a

    CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg

    £810,903,137

Key details

Country
United Kingdom
Status
In delivery
Category
Goods
Estimated value
£1,520,432,295
Procedure
Open
Contract type
Framework agreement
SME suitable
Yes
Published
19 June 2025
Questions by
7 July 2025
Deadline
Closed
Classification (CPV)
Pharmaceutical productsVarious medicinal products

Award outcome

Awarded value
£2,254,670,118
Award date
30 July 2025
Contract period
1 December 2025 → 31 May 2027
Winners
  • ABBVIE LTD
  • ALIMERA SCIENCES LIMITED
  • Abbvie Ltd
  • Alimera Sciences
  • BAYER PUBLIC LIMITED COMPANY
  • BIOGEN IDEC LIMITED
  • BIOSIMILAR COLLABORATIONS IRELAND LIMITED
  • Bayer Plc
  • Biogen
  • Biosimilar Collaborations Ireland Limited
  • CELLTRION HEALTHCARE UNITED KINGDOM LIMITED
  • Celltrion Healthcare United Kingdom Limited
  • MDBIOLOGICS LTD
  • NOVARTIS PHARMACEUTICALS UK LIMITED
  • Novartis Pharmaceuticals UK Ltd
  • ORION PHARMA (UK) LIMITED
  • Orion Pharma (UK) Ltd
  • Outlook Therapeutics, Inc.
  • ROCHE PRODUCTS LIMITED
  • Roche Products Ltd
  • SANDOZ LIMITED
  • TEVA UK LIMITED
  • THORNTON & ROSS LIMITED
  • Teva UK Limited
  • Thornton and Ross Ltd

Contract ending soon? Skim tracks incumbents and flags recompetes early. Start for Free to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract

    6 October 2025

  2. Contract

    1 August 2025

  3. Tender Update

    19 June 2025

  4. Contract Notice

    19 June 2025

More from NHS ENGLAND

Other contracts from the same contracting authority. 13 live opportunities · 817 awarded contracts on their hub.

See all their tenders →
Open for bidsUnited KingdomServices£825,000

NHS Graduate Management Training Scheme(GMTS) Engineering and Estates Management - NHSE

Deadline 8 October 2026

Open for bidsUnited KingdomServices£85,200,000

Midlands Critical Care Transfer Service Ambulance Provider

Deadline 6 October 2026

Open for bidsUnited KingdomServices£2,600,000

Agenda for Change Job Evaluation Digital System

Deadline 5 October 2026

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

Start for FreeSee more tenders

How to win this tender

Skim reads the notice and every document attached to it, scores the fit against your company profile for a clear bid or no-bid call, then drafts each answer from your own evidence and past bids. You review, refine and submit — on time, with every requirement covered.

See exactly how Skim’s agents do this →

Comparing platforms? Skim is set against the alternatives for pre-tender intelligence, tender management software and bid management software.

Find tenders like this before your competitors do.

Skim scans every portal daily and scores each tender against your profile. Start for free and see the tenders you are missing.

See more tenders